|
000
| 02288cam 2200397zi 4500 |
|---|
| 001 | 9.910768 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107182215 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 220502t20222022onc ob f000 0 eng d |
|---|
| 020 | |a9780660433523 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-308/2022E-PDF |
|---|
| 245 | 00|aRecommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
|---|
| 264 | 1|a[Ottawa] : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2022. |
|---|
| 264 | 4|c©2022 |
|---|
| 300 | |a1 online resource (151 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Publication date: June 2022." |
|---|
| 500 | |a"Protecting and empowering Canadians to improve their health." |
|---|
| 500 | |aAt head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |aIssued also in French under title: Utilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons. |
|---|
| 504 | |aIncludes bibliographical references (pages 76-97). |
|---|
| 520 | |a"The objective of this advisory committee statement is to review evidence and develop guidance on strategies to prevent severe consequences of Respiratory syncytial virus (RSV) infection in children at high risk of severe RSV disease by administration of monoclonal antibody"--Guidance objective, page 8. |
|---|
| 650 | 0|aPalivizumab|zCanada. |
|---|
| 650 | 0|aRespiratory syncytial virus|zCanada. |
|---|
| 650 | 0|aInfants|xDiseases|zCanada. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tUtilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons.|w(CaOODSP)9.910769 |
|---|
| 794 | |tRecommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants.|w(CaOODSP)9.913694 |
|---|
| 856 | 40|qPDF|s1.36 MB|uhttps://publications.gc.ca/collections/collection_2022/aspc-phac/HP40-308-2022-eng.pdf |
|---|